In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 ...

Other developments include Teva Pharmaceuticals' launch of the first generic version of Victoza, a GLP-1 drug originally approved in 2010 for Type 2 diabetes and later for reducing cardiovascular ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who are 10 years old and up with Type 2 diabetes. The liraglutide injection, ...